White Papers published by AII

White Paper

"Preventing Protein Instability: How I2F Reduces Bubbles to Mitigate Agitation-Induced Denaturation and Aggregation"

Protein instability in biopharmaceuticals leads to reduced efficacy, waste, and higher costs. This white paper introduces I2F, a breakthrough device that eliminates air bubbles during medication preparation and administration, preventing agitation-induced denaturation and aggregation. Discover how I2F enhances stability, efficiency, and quality in handling sensitive formulations.

White Paper

"Reducing Hypersensitivity Reactions in Immunoglobulin Therapy with I2F"

This white paper explores how the innovative I2F device can reduce hypersensitivity reactions during immunoglobulin (IG) therapy by minimizing protein destabilization caused by agitation and bubble formation. Backed by scientific insights and clinical rationale, the paper highlights I2F’s potential to enhance patient safety and improve outcomes in both human and veterinary applications.

White Paper

"I2F: Enhancing Biologic Safety and Reducing Cost — A Value Proposition for Insurers"

This white paper presents a compelling value proposition for insurers, demonstrating how the I2F device enhances the safety of biologic therapies by reducing agitation-induced protein degradation, which can lead to adverse reactions. By improving drug stability and decreasing costly complications, I2F offers a strategic solution to help insurers manage risk, lower healthcare expenditures, and support better patient outcomes.